Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Benralizumab in Patients With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)

NCT04157335 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04157335
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04157335 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Benralizumab in Patients With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Terminated
Start date
November 25, 2019
Completion date
April 7, 2025
Enrollment
295 (actual)
Sites
116

Conditions

As the registry lists them; a condition with its own page is linked.

eosinophilic chronic rhinosinusitis, nasal polyposis